Single and dual agonists The fundamental difference between these two molecules is that semaglutide is a GLP-1 agonist, i.e., it has a strong structural similarity (95%) with this hormone and specifically activates its receptor, while tirzepatide is a dual agonist, i.e., it has a hybrid structure that allows it to activate both GLP-1 and GIP receptors (Figure 2)
Compounded GLP-1 options through platforms like PlexusDx start at $129/month (Microdose Protocol) or $189/mo for full-strength semaglutide, providing significant savings
NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production
SURPASS J-combo study comparing people with T2DM in a Japanese population with a high HbA1c on oral antihyperglycemic monotherapy on 5, 10, or 15 mg of once weekly tirzepatide for 52 weeks showed an improvement of glycemic and lipid control, weight loss and reduction in blood pressure [57]
With respect to body weight, a higher baseline body-mass-index is a predictor of absolute weight reduction, albeit with substantial body weight loss even in those with a BMI 50 years with either chronic kidney disease and an eGFR of less than 60 ml/min per 1.73 m 2 or history of congestive heart failure (NY Heart Association Class II or III)
Notably, considerable metabolic improvement was achieved at relatively low doses of GLP1/E, thus increasing the safety margin of this compound, which did not cause uterotrophic effects per se
